ストックスクリーナーアプリを入手
3.75
10.29%
0.35
アフターアワーズ：
3.90
0.15
+4.00%
前日終値:
$3.40
開ける：
$3.56
24時間の取引高:
85,239
Relative Volume:
1.77
時価総額：
$50.31M
収益：
-
当期純損益:
$-11.73M
株価収益率:
-2.7123
EPS:
-1.3826
ネットキャッシュフロー:
$-10.37M
1週間 パフォーマンス:
+13.64%
1か月 パフォーマンス:
-1.32%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.4199
$4.00
1週間の範囲:
$3.00
$4.15
52週間の値動き範囲:
$1.80
$4.99
Medicus Pharma Ltd Stock (MDCX) Company Profile
名前
Medicus Pharma Ltd
セクター
電話
610-540-7515
住所
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
MDCX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
3.75 | 50.31M | 0 | -11.73M | -10.37M | -1.3826 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicus Pharma Ltd (MDCX) 最新ニュース
Will Medicus' D-MNA Prove To Be A Non-Invasive, Effective Alternative To Mohs Surgery For BCC? - RTTNews
Medicus Pharma Ltd. SEC 10-K Report - TradingView
Medicus Pharma Ltd. (MDCX) reports earnings - Quartz
Healthcare Disruptors: AI, Telehealth and Cost Savings - Value The Markets
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out - WRAL.com
ValueTheMarkets Insights: Healthcare Climbs as Tech Stumbles in 2025 Shift - WRAL.com
Healthcare Climbs as Tech Stumbles in 2025 Shift - Value the Markets
While Big Pharma Stalls, One Small-Cap Breaks Out - Value the Markets
Medicus Pharma cancels shareholder meeting notice By Investing.com - Investing.com Australia
Medicus Pharma cancels shareholder meeting notice - Investing.com
Pinpointing Hidden Stock Winners in a Volatile Market - Value the Markets
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%! - Value The Markets
Medicus Pharma announces annual meeting date - Investing.com
Medicus Pharma announces annual meeting date By Investing.com - Investing.com Australia
Advancing Oncology: Innovations in Treatment and Detection - Value The Markets
See Why Some Investors Are Watching This Biotech Company - Value The Markets
Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity - Value The Markets
The Biotech Stocks Tackling the World’s Most Common Cancer - Value The Markets
Medicus Pharma - The Pharma Letter
Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials - TipRanks
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering - Newsfile
Medicus Pharma CEO discusses latest skin cancer trial resultsICYMI - Proactive Investors UK
Encouraging Interim Data for Innovative Skin Cancer Patch - Value The Markets
Small cap wrap: G Mining Ventures, Wedgemount Resources, Medicus Pharma... - Proactive Investors UK
Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating - TipRanks
Medicus Pharma unveils pricing of financing to advance skin cancer treatment - Proactive Investors Australia
Can This $4.2M Funding Advance Medicus Pharma's Novel Skin Cancer Patch to Market? - StockTitan
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering - Newsfile
Clinical Study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE - Proactive Investors USA
Small cap wrap: Petro-Victory Energy, NexTech3D.ai, Medicus Pharma, Nano One Technology... - Proactive Investors UK
Market movers: Tesla, Marvell, Petro-Victory, Medicus Pharma... - Proactive Investors USA
Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial - Value the Markets
High Demand, Few Options: The Skin Cancer Treatment Gap - Value The Markets
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results - Proactive Investors Australia
Medicus Pharma Announces Positively Trending Interim Analysis For SKNJCT-003 Phase 2 Clinical Study - Marketscreener.com
Medicus Pharma announces positively trending interim analysis for SKNJCT-003 - TipRanks
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - GlobeNewswire
Can This New Skin Cancer Treatment Replace Surgery? Phase 2 Trial Reveals Promising Results - StockTitan
A Breakthrough in Non-Invasive Skin Cancer Treatment - Value The Markets
Why Reddit Stock Lost 19% in February - The Globe and Mail
Sea (SE) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Prediction: 3 Stocks That'll Be Worth More Than Apple 5 Years From Now - The Globe and Mail
Extended Session Rally For Medicus (MDCX) Stock, Fueled By Regulatory Success - Stocks Telegraph
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical - GlobeNewswire
Medicus Pharma Submits Phase 2 Clinical Trial Design For Non-Invasive BCC Treatment To UAE - Nasdaq
Small cap headlines: Alvopetro Energy, Delivra Health, Medicus Pharma, Aftermath Silver... - Proactive financial news
Medicus Pharma expands basal cell carcinoma trial in the Middle East - Proactive Investors Australia
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive financial news
Medicus Pharma submits Phase 2 carcinoma clinical design in UAE - TipRanks
Medicus Pharma submits Phase 2 skin cancer trial design to UAE Department of Health - Proactive Investors Australia
Medicus Pharma Ltd (MDCX) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):